Literature DB >> 24065527

ELISA examining urinary angiotensinogen as a potential indicator of intrarenal renin-angiotensin system (RAS) activity: a clinical study of 128 chronic kidney disease patients.

Xiao-yan Zhang1, Xiao-qiang Ding, Wen-Lv Lv, Jie Teng, Yi-Hong Zhong.   

Abstract

In the current study, we measured urinary angiotensinogen (AGT) through enzyme-linked immunoadsordent assay (ELISA) and analyzed its correlation with intrarenal renin-angiotensin system (RAS) activity in 128 chronic kidney disease (CKD) patients. Urinary and plasma renin activity, AGT, angiotensin II (Ang II) and aldosterone levels were also measured by radioimmunoassay (RIA) or ELISA in these participants. Further, the expression level of intrarenal renin, AGT, Ang II and Ang II receptors were examined by immunohistochemistry staining (IHCS) in 72 CKD patients. Their correlations with urinary AGT were also analyzed. We found that the urinary AGT level was positively correlated with hypertension (ρ = 0.28, P < 0.01), urinary protein (r = 0.38, P < 0.01), urinary Ang II (r = 0.29, P < 0.05), urinary type IV collagen (Col IV) (r = 0.56, P < 0.01), and was negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.28, P < 0.01), urinary sodium (r = -0.22, P < 0.05) and serum AGT (r = -0.27, P < 0.01). Multiple regression analysis indicated low serum AGT (P < 0.01), high urinary protein (P < 0.01), high urinary Ang II (P < 0.05) and high urinary Col IV (P < 0.01) were correlated significantly with high urinary AGT. Urinary AGT level was positively correlated with intrarenal expression level of AGT (ρ = 0.46, P < 0.01), Ang II (ρ = 0.56, P < 0.01) and Ang II type 1 receptor (ρ = 0.32, P < 0.01), as detected by IHCS. Together, these data suggest that urinary AGT might be a potential biomarker of intrarenal RAS and Ang II activities in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065527     DOI: 10.1007/s11033-013-2687-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  20 in total

Review 1.  Angiotensin II: a pivotal factor in the progression of renal diseases.

Authors:  G Wolf
Journal:  Nephrol Dial Transplant       Date:  1999       Impact factor: 5.992

Review 2.  Implications of species difference for clinical investigation: studies on the renin-angiotensin system.

Authors:  N K Hollenberg
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

3.  Kinetics of the reaction of human renin with natural substrates and tetradecapeptide substrate.

Authors:  L Favre; M B Vallotton
Journal:  Biochim Biophys Acta       Date:  1973-12-19

4.  Kinetics of the human renin and human substrate reaction.

Authors:  A B Gould; D Green
Journal:  Cardiovasc Res       Date:  1971-01       Impact factor: 10.787

5.  Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy.

Authors:  Akira Nishiyama; Yoshio Konishi; Naro Ohashi; Takashi Morikawa; Maki Urushihara; Isseki Maeda; Masahiro Hamada; Masatsugu Kishida; Hirofumi Hitomi; Nobuo Shirahashi; Hiroyuki Kobori; Masahito Imanishi
Journal:  Nephrol Dial Transplant       Date:  2010-07-07       Impact factor: 5.992

6.  Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity.

Authors:  Maki Urushihara; Shuji Kondo; Shoji Kagami; Hiroyuki Kobori
Journal:  Am J Nephrol       Date:  2010-02-15       Impact factor: 3.754

7.  In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys.

Authors:  I A Darby; C Sernia
Journal:  Cell Tissue Res       Date:  1995-08       Impact factor: 5.249

8.  Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats.

Authors:  Hiroyuki Kobori; Akira Nishiyama
Journal:  Biochem Biophys Res Commun       Date:  2004-03-12       Impact factor: 3.575

9.  Genetic deletion of AT1a receptors attenuates intracellular accumulation of ANG II in the kidney of AT1a receptor-deficient mice.

Authors:  Xiao C Li; L Gabriel Navar; Yuan Shao; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2007-05-30

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  5 in total

1.  Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.

Authors:  Ramanathan Gnanasambandan; Ramprasad Elumalai; Periyasamy Soundararajan; Bhaskar V K S Lakkakula
Journal:  Clin Exp Nephrol       Date:  2015-10-19       Impact factor: 2.801

2.  Changes of urinary angiotensinogen concentration and its association with urinary proteins in diabetic rats.

Authors:  Zhen Zhuang; Qiong Bai; A Lata; Yaoxian Liang; Danxia Zheng; Yue Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

4.  Urinary angiotensinogen as a potential biomarker of intrarenal renin-angiotensin system activity in Chinese chronic kidney disease patients.

Authors:  Z Xu; B Xu; C Xu
Journal:  Ir J Med Sci       Date:  2014-03-25       Impact factor: 1.568

5.  Effect of unilateral nephrectomy on urinary angiotensinogen levels in living kidney donors: 1 year follow-up study.

Authors:  Zeynep Kendi Celebi; Ahmet Peker; Sim Kutlay; Senem Kocak; Acar Tuzuner; Sehsuvar Erturk; Kenan Keven; Sule Sengul
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017 Oct-Dec       Impact factor: 1.636

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.